Jeffrey Chodakewitz an Insider in Vertex Pharmaceuticals (VRTX) Sold 3,438 Shares; 14 Analysts Covering Cypress Semiconductor (CY)

Among 21 analysts covering Cypress Semiconductor Corporation (NASDAQ:CY), 14 have Buy rating, 1 Sell and 6 Hold. Therefore 67% are positive. Cypress Semiconductor Corporation had 66 analyst reports since August 31, 2015 according to SRatingsIntel. As per Thursday, June 22, the company rating was maintained by Mizuho. The stock of Cypress Semiconductor Corporation (NASDAQ:CY) earned “Hold” rating by SunTrust on Friday, December 1. The stock of Cypress Semiconductor Corporation (NASDAQ:CY) has “Neutral” rating given on Friday, October 27 by Credit Suisse. The stock has “Buy” rating by SunTrust on Wednesday, October 11. The firm has “Buy” rating given on Friday, June 23 by Loop Capital Markets. Craig Hallum maintained Cypress Semiconductor Corporation (NASDAQ:CY) on Friday, April 29 with “Buy” rating. The firm earned “Equal-Weight” rating on Tuesday, October 31 by Barclays Capital. On Friday, October 9 the stock rating was maintained by Topeka Capital Markets with “Buy”. Oppenheimer maintained Cypress Semiconductor Corporation (NASDAQ:CY) on Friday, January 29 with “Outperform” rating. Pacific Crest maintained Cypress Semiconductor Corporation (NASDAQ:CY) rating on Wednesday, March 29. Pacific Crest has “Overweight” rating and $17 target. See Cypress Semiconductor Corporation (NASDAQ:CY) latest ratings:

19/12/2017 Broker: PiperJaffray Rating: Overweight New Target: $20 Initiates Coverage On
13/12/2017 Broker: Morgan Stanley Rating: Underweight New Target: $14.5 Maintain
12/12/2017 Broker: Susquehanna Rating: Buy New Target: $20.0
06/12/2017 Broker: Mizuho Rating: Buy New Target: $18.0 Maintain
05/12/2017 Broker: Craig Hallum Rating: Buy New Target: $21.0 Maintain
01/12/2017 Broker: SunTrust Old Rating: Buy New Rating: Hold Old Target: $17 Downgrade
14/11/2017 Broker: Craig Hallum Rating: Buy New Target: $21.0 Maintain
31/10/2017 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
26/10/2017 Broker: Bank of America Rating: Buy New Target: $21.0 Maintain
27/10/2017 Broker: Credit Suisse Rating: Neutral Old Target: $14 New Target: $15 Maintain

After the publishing of a form filled with U.S. Security & Exchange Commission; a insider deal became apparent. The EVP GMDA – CMO of Vertex Pharmaceuticals Inc Ma, Jeffrey Chodakewitz; finalized a deal in the open market by unloading 3,438 shares at the average share price of $151.8 of the corporation worth near $521,895 USD. Jeffrey Chodakewitz at present has ownership of 0.02% of the Company’s total market cap with ownership of 54,424 shares. 

The stock increased 0.53% or $0.085 during the last trading session, reaching $16.255. About 2.81M shares traded. Cypress Semiconductor Corporation (NASDAQ:CY) has risen 39.45% since January 4, 2017 and is uptrending. It has outperformed by 22.75% the S&P500.

Since August 1, 2017, it had 0 insider buys, and 4 selling transactions for $5.18 million activity. 3,000 shares were sold by GOPALSWAMY SUDHIR, worth $46,538. NAZARIAN DANA sold $3.53M worth of Cypress Semiconductor Corporation (NASDAQ:CY) on Friday, August 4. Another trade for 30,000 shares valued at $422,154 was made by WISHART MICHAEL S on Tuesday, August 1. The insider Thad Trent sold $1.18M.

Cypress Semiconductor Corporation designs, develops, makes, markets, and sells embedded system solutions worldwide. The company has market cap of $5.42 billion. It operates in two divisions, Microcontroller and Connectivity Division and Memory Products Division. It currently has negative earnings. The Microcontroller and Connectivity Division provides microcontroller , analog, and wireless and wired connectivity solutions, including Traveo automotive MCUs; programmable system-on-chip MCUs; ARM Cortex-M4, -M3, and -M0+ MCUs; R4 CPUs; analog power management integrated circuits and energy harvesting solutions; CapSense capacitive-sensing controllers; TrueTouch touchscreen and fingerprint reader products; USB controllers comprising solutions for the USB-C and USB power delivery standards; and Wi-Fi, Bluetooth, Bluetooth low energy and ZigBee radios, and WICED development platforms for the Internet of things (IoT).

Investors sentiment decreased to 1.08 in 2017 Q3. Its down 0.42, from 1.5 in 2017Q2. It is negative, as 34 investors sold Cypress Semiconductor Corporation shares while 109 reduced holdings. 51 funds opened positions while 104 raised stakes. 313.76 million shares or 0.67% more from 311.68 million shares in 2017Q2 were reported. Northpointe Cap Ltd owns 744,949 shares for 1.2% of their portfolio. Capital One Association holds 0.1% of its portfolio in Cypress Semiconductor Corporation (NASDAQ:CY) for 97,538 shares. Cannell Peter B & Commerce holds 0.17% or 330,800 shares. Nationwide Fund has invested 0.05% in Cypress Semiconductor Corporation (NASDAQ:CY). Nuveen Asset Limited Liability Com holds 1.33 million shares or 0.13% of its portfolio. Employees Retirement Association Of Colorado invested in 73,252 shares or 0.01% of the stock. Waddell And Reed Financial holds 18.63 million shares. Tdam Usa Inc owns 135,869 shares for 0.12% of their portfolio. Weaver C Barksdale & Assoc Inc holds 0.01% or 799 shares in its portfolio. Automobile Association holds 0.1% or 2.35 million shares. Creative Planning owns 42,234 shares for 0% of their portfolio. Robertson Opportunity Cap Limited Liability Company, Texas-based fund reported 435,000 shares. Catawba Management Va has invested 0.11% in Cypress Semiconductor Corporation (NASDAQ:CY). Panagora Asset Mngmt accumulated 17,524 shares or 0% of the stock. Natixis Asset Mngmt holds 86,118 shares.

Among 27 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 23 have Buy rating, 0 Sell and 4 Hold. Therefore 85% are positive. Vertex Pharmaceuticals has $205.0 highest and $85.0 lowest target. $168.30’s average target is 9.66% above currents $153.48 stock price. Vertex Pharmaceuticals had 80 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Hold” rating by Jefferies on Wednesday, September 9. The rating was maintained by H.C. Wainwright on Thursday, October 26 with “Hold”. Cowen & Co maintained it with “Hold” rating and $10500 target in Wednesday, July 5 report. The firm earned “Buy” rating on Tuesday, July 18 by Oppenheimer. The firm earned “Outperform” rating on Friday, June 2 by Oppenheimer. The rating was maintained by Jefferies with “Buy” on Wednesday, July 19. Maxim Group maintained the shares of VRTX in report on Wednesday, July 19 with “Buy” rating. The company was upgraded on Wednesday, July 19 by Janney Capital. H.C. Wainwright upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Friday, October 30 to “Buy” rating. The rating was maintained by Leerink Swann on Tuesday, March 8 with “Outperform”.

Since July 31, 2017, it had 0 insider purchases, and 20 insider sales for $62.07 million activity. LEIDEN JEFFREY M also sold $1.69M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, July 31. 81,290 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $11.77M were sold by Arbuckle Stuart A. On Tuesday, October 31 the insider SMITH IAN F sold $10.88M. $287,360 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by ALTSHULER DAVID. $5.80M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Sachdev Amit. Shares for $131,571 were sold by Silva Paul M on Monday, July 31. $521,198 worth of stock was sold by Chodakewitz Jeffrey on Monday, October 2.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $38.82 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 197.78 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on January, 24. They expect $0.28 earnings per share, up 115.38% or $0.15 from last year’s $0.13 per share. VRTX’s profit will be $70.81 million for 137.04 P/E if the $0.28 EPS becomes a reality. After $0.24 actual earnings per share reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts 16.67% EPS growth.

Investors sentiment increased to 1.62 in Q3 2017. Its up 0.11, from 1.51 in 2017Q2. It is positive, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. 13 are held by Jnba Fincl. Schwab Charles Investment Management reported 0.12% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Jefferies Grp Limited Liability Corporation accumulated 34,300 shares or 0.03% of the stock. Covington Cap Mgmt has 75 shares. Moreover, Fortaleza Asset Mngmt has 0.73% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 2,615 shares. Arcadia Inv Mngmt Mi owns 160 shares. Canada Pension Plan Board holds 0.06% or 189,655 shares. Commonwealth Equity Services has invested 0.01% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Lazard Asset Mngmt Ltd Liability accumulated 173,422 shares. Morgan Stanley reported 0.04% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Atalanta Sosnoff Cap Lc invested 2.05% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 36 are held by Contravisory Investment Inc. Lmr Ptnrs Llp reported 5,340 shares. Ballentine Ptnrs Limited Liability Corporation stated it has 1,825 shares or 0.02% of all its holdings. Pennsylvania accumulated 0.01% or 1,445 shares.

The stock increased 0.97% or $1.47 during the last trading session, reaching $153.48. About 873,562 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since January 4, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.